News room - Egetis Therapeutics

1 December, 2015 PLEDPHARMA PRESENTS NEW IN-DEPTH FOLLOW-UP DATA FROM PLIANT STUDY - PLEDOX® SHOWN TO REDUCE CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY BY 75 PERCENT News English IR Optional

19 November, 2015 PLEDPHARMA REPORTS CONSTRUCTIVE MEETING WITH THE FDA AND PRESENTS NEW FOLLOW-UP DATA News English IR Optional

11 November, 2015 Nomination Committee for the 2016 Annual General Meeting in PledPharma AB News English IR Optional

20 October, 2015 Interim report third quarter 2015 News English Report Interim Q3 IR Optional

22 September, 2015 KEY COMPOUND PATENT FOR PLEDOX® AND ALADOTE® SET TO GAIN US APPROVAL News English IR Optional

18 August, 2015 Interim report second quarter 2015 News English Report Interim Q2 IR Optional

26 June, 2015 PLEDPHARMA PRESENTS ADDITIONAL RESULTS FROM A PHASE IIB STUDY WITH PLEDOX® AT THE SCIENTIFIC CONFERENCE MASCC News English IR Optional

21 April, 2015 Interim report first quarter 2015 News English Report Interim Q1 IR Optional

29 March, 2015 PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX® REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT News English IR Optional

17 February, 2015 Year-end report 2014 News English Report Interim Yearend IR Optional

Press releases